ATRA
NASDAQ
$9.90
Atara Biotherapeutics Inc (ATRA)
Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California.
Sector:
Healthcare
Industry:
Biotechnology
Hold
Target: $13.67 (+38.08%)
Market Cap
$90M
Free Cash Flow Yield
-28.84%
Beta (5Y)
1.37
Price Chart
Valuation
Market Cap$90M
Forward P/E232.56
P/S4.10
P/B16.14
Profitability
Total Revenue (TTM)$23M
Gross Profit (TTM)-$2.70M
EBITDA-$5.96M
Profit Margin-40.9%
Operating Margin-653%
EPS-$1.21
Financial Health
Free Cash Flow Yield-28.84%
Growth & Risk
EPS 5Y CAGR-58.48%
FCF 5Y CAGR-32.51%
Beta (5Y)1.37
Sharpe Ratio0.83